Navigation Links
Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Date:5/5/2013

Claremont CA (PRWEB) May 05, 2013

Removing embedded bacteria from biofilms in wounds remains a challenge to doctors and caregivers. Likewise, veterinarians face similar challenges treating their zoo patients. Synedgen will report compelling data on new treatments against wound biofilms at a poster session at the 113th General Meeting of the American Society for Microbiology (asm2013) on May 18-21, 2013, at the Colorado Convention Center in Denver Colorado.

The poster, Antibacterial and Wound Healing Enhancement of PAAG in Minor Species, highlights the antibacterial and biofilm-reducing activity of Synedgen’s Synoplex® rinse. Data will be presented for efficacy against bacteria from elephant wounds and for Klebsiella pneumoniae biofilms. Data from additional collaborative studies evaluating Synoplex in the treatment of chronic elephant and rhinoceros wounds, including foot-disease, pressure ulcers, and infected glands that were not responding well to conventional treatment will also be presented. Synoplex is approved for marketing by the FDA as a treatment for wounds in elephants and rhinoceros.

Bacteria isolated from elephant wounds were all reduced more than 1000 fold after 1-hour treatment with Synoplex. K. pneumonia biofilms were reduced by more than 1000 fold after 5-hour treatment. Epithelial cells, which are responsible for the initial stages of regeneration of tissue, grew to cover at least twice more surface area than other wound treatments and control. Treated minor species showed significant improvement in wound healing and successful resolution of most wounds.
Synedgen’s VP of Research Stacy Townsend PhD will present the results on Tuesday May 21, 2013 at 1:00 PM - 2:45 PM at Poster board # 2194.

“As demonstrated by these studies, Synoplex provides a highly effective prophylactic and therapeutic treatment for controlling and preventing bacterial biofilms associated with chronic and acute dermal wounds including foot disease in minor species,” remarked Townsend. “The non-toxic nature of Synoplex is also beneficial in a large animal setting.”

Synoplex is available directly from Synedgen. For pricing and ordering information, please contact Synedgen at info(at)synedgen(dot)com.

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10700553.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen Announces Issuance of Patent to Optimize Animal Health
2. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
3. Small Business Online SEO Class Enrolling Now, Announces JM Internet
4. Anthera Announces First Quarter 2013 Financial Report and Conference Call
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):